Are New Alzheimer’s Drugs Actually Effective? Expert Debate and Analysis

A meta-analysis conducted by the Cochrane Collaboration has sparked significant debate among medical professionals by concluding that amyloid-clearing drugs for Alzheimer’s disease do not provide a clinically meaningful benefit to patients.

The review pooled data from 17 trials involving seven different medicines designed to eliminate amyloid beta proteins from the brain. According to the findings, the effects of these drugs at the 18-month mark were either absent or trivial on standard cognitive tests.

Findings on Cognitive Impact and Safety Risks

The Cochrane Collaboration, a global nonprofit recognized for producing objective evaluations of evidence, reported that removing amyloid from the brain does not improve cognition or slow the rate of cognitive decline.

View this post on Instagram about Cochrane, Alzheimer

Lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy, stated that the evidence suggests these drugs make no meaningful difference to patients.

Beyond the lack of cognitive gain, the meta-analysis highlighted serious safety concerns. The review found that these medications increase the risk of brain swelling and bleeding.

The idea that removing the amyloid will benefit patients was refuted by our results.

Edo Richard, professor of Neurology at Radboud University Medical Centre in the Netherlands

The Amyloid Hypothesis and Drug Development

The drugs in question target amyloid beta proteins, which form gummy deposits known as amyloid plaques in the brains of people with Alzheimer’s. For years, scientists have operated on the theory that these plaques are a primary cause of the disease’s memory-robbing effects.

However, the impact of these plaques on disease progression remains unclear. Some researchers argue that the approach of attacking plaques has been flawed. For example, aducanumab, a drug designed to remove A-beta, was withdrawn from the market on January 31, 2024.

Neurologist Mike Greicius of Stanford Medicine has noted that while earlier drugs treated symptoms, they did not slow the underlying destruction of nerve circuitry. He suggests that the clinical benefits of plaque-attack drugs have proved less than stellar.

Professional Dispute and Criticism of the Review

The Cochrane analysis has faced criticism from various Alzheimer’s experts and clinicians. Some U.S.-based doctors dispute the methods and the 18-month time frame used in the meta-analysis, arguing that newer drugs may still help specific patients and that treatment choices should be individualized.

Critics of the review suggest that the analysis unfairly grouped failed drugs with two more recently approved medications. Some experts argue that applying such strict standards to these drugs would have prevented the development of critical medications for other diseases, such as cancer or AIDS.

The debate is further complicated by regulatory differences. While some drugs have seen approval in certain regions, the European Medical Agency has issued rulings against the latest anti-amyloid drugs, emphasizing ongoing concerns regarding their safety and efficacy.

Current State of Treatment

The controversy underscores a broader struggle in dementia research. While the buildup of amyloid plaque is a hallmark of Alzheimer’s, the failure of several high-cost drugs to produce meaningful cognitive improvements has led some scientists to suggest that the medical community may have been treating the disease incorrectly.

As of April 2026, the medical community remains divided between those who view the Cochrane findings as a definitive refutation of the amyloid-clearing approach and those who believe the analysis has major limitations and that targeted therapy remains a viable path forward.